These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21654615)

  • 21. [Selective Estrogen Receptor Modulators (SERMs) for prevention and treatment of postmenopausal osteoporosis].
    Birkhäuser M
    Ther Umsch; 2012 Mar; 69(3):163-72. PubMed ID: 22403109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
    Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
    Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Next generation selective estrogen receptor modulators].
    Chaki O
    Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.
    Harvey JA; Holm MK; Ranganath R; Guse PA; Trott EA; Helzner E
    Menopause; 2009; 16(6):1193-6. PubMed ID: 19503006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
    Kanis JA; Johansson H; Oden A; McCloskey EV
    Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].
    Legrand E; Hoppé E; Chappard D; Audran M
    Gynecol Obstet Fertil; 2006 May; 34(5):423-8. PubMed ID: 16697240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective estrogen receptor modulators: the future in menopausal treatment.
    Palacios S
    Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preventing osteoporosis in symptomatic postmenopausal women.
    Gallagher JC; Levine JP
    Menopause; 2011 Jan; 18(1):109-18. PubMed ID: 20661164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis.
    Stump AL; Kelley KW; Wensel TM
    Ann Pharmacother; 2007 May; 41(5):833-9. PubMed ID: 17426077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective estrogen receptor modulators and postmenopausal health.
    Roe EB; Chiu KM; Arnaud CD
    Adv Intern Med; 2000; 45():259-78. PubMed ID: 10635051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
    Calaf Alsina J; Coronado Martín PJ
    Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
    Burckhardt P
    Schweiz Med Wochenschr; 1999 Dec; 129(49):1926-30. PubMed ID: 10635085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
    Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
    Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Selective estrogen receptor modulators (SERMs)].
    Matsumoto T
    Clin Calcium; 2006 Sep; 16(9):1520-25. PubMed ID: 16951478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical experience with raloxifene].
    Szúcs J; Pávó I; Jurida N
    Orv Hetil; 2000 Jan; 141(5):237-40. PubMed ID: 10697982
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.
    Ohta H; Solanki J
    Osteoporos Int; 2015 Mar; 26(3):849-63. PubMed ID: 25448837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.